Reply
Reply. We are grateful for Dr Donzelli et al and Dr Bronswijk for their interest in our randomized controlled trial evaluating the efficacy1 as well as the safety2 of pantoprazole in reducing gastroduodenal events in patients taking rivaroxaban or aspirin. Dr Bronswijk states that the dose of rivaroxaban is low and perhaps we would have s een more upper gastrointestinal (GI) events if we had evaluated a higher dose. However, the present regimen of low dose rivaroxaban (2.5 mg twice daily) plus low-dose aspirin was effective in reducing cardiovascular events and deaths in the population studied and this has led to approval for use of rivaroxaban plus aspirin in these patients.
Source: Gastroenterology - Category: Gastroenterology Authors: Paul Moayyedi, John W. Eikelboom, Salim Yusuf Tags: Correspondence Source Type: research
More News: Aspirin | Cardiology | Cardiovascular | Gastroenterology | Heart | Pantoprazole | Protonix